Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) presented new data on two molecules from its wholly owned PKR activator program demonstrating the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE